secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053931
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics Q1 net loss $31.4M; cash $201.9M; pipeline on track for H2 2024 data
--------------------------------------------------------------------------------

- Net loss $31.4M ($0.42/diluted share) vs $27.7M ($0.58) in Q1 2023; R&D spend $27.4M up from $21.8M.
- Cash, equivalents & marketable securities $201.9M as of March 31, 2024; cash runway expected into 2026.
- PRT3789 (SMARCA2 degrader) and PRT2527 (CDK9 inhibitor) on track for initial proof-of-concept data H2 2024.
- PRT7732 oral SMARCA2 degrader expected to enter Phase 1 in H2 2024; IND-enabling studies ongoing.
- Appointed Sean Brusky as CBO and Robert Doody as SVP, IR in April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024053931/0000950170-24-053931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024053931/prld-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer